697739-20-1

Basic information

• Product Name: 2-CHLORO-4-(3-TRIFLUOROMETHYLPHENYL)PYRIDINE
• Synonyms: 2-CHLORO-4-(3-TRIFLUOROMETHYLPHENYL)PYRIDINE
• CAS NO: 697739-20-1
• Molecular Formula: C₁₂H₇ClF₃N
• Molecular Weight: 0
• Mol File: 697739-20-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-CHLORO-4-(3-TRIFLUOROMETHYLPHENYL)PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-4-(3-TRIFLUOROMETHYLPHENYL)PYRIDINE(697739-20-1)
• EPA Substance Registry System: 2-CHLORO-4-(3-TRIFLUOROMETHYLPHENYL)PYRIDINE(697739-20-1)

Safety Data

• Hazardous Substances Data: 697739-20-1(Hazardous Substances Data)

Upstream product

• 1202574-23-9 C₁₂H₈F₃NO 

Downstream Products

• 1202574-29-5 3-methoxyphenyl-[4-(3-trifluoromethyl-phenyl)l-pyridin-2-yl]-amine 
• 1202574-31-9 4-methoxyphenyl-[4-(3-trifluoromethyl-phenyl)l-pyridin-2-yl]-amine 
• 1202574-32-0 naphthalen-2-yl-[4-(3-trifluoromethyl-phenyl)l-pyridin-2-yl]-amine 
• 1202574-30-8 4-ethylphenyl-[4-(3-trifluoromethyl-phenyl)l-pyridin-2-yl]-amine 

Relevant articles and documents

Synthesis of 4-Aryl-2-aminopyridine derivatives and related compounds

A short, efficient, and high-yielding synthesis of 4-aryl-2-aminopyridine derivatives has been developed. The route employs two palladium-catalyzed processes, the Suzuki reaction and the Buchwald-Hartwig amination, as the key steps. The same approach has

AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN

the present invention provides a compound of formula (I): wherein V represents NR5, O, S, SO or S(O)2; W and X each independently represent CH or N; Y represents N, CH or C-Ar2, with the proviso that at least one, but no more than two, of W, X and Y are N; Z represents CH or C-Ar2, with the proviso that when Y is N or CH then Z is C-Ar2, and with the further proviso that when Y is C-Ar2 then Z is CH; Ar1 represents a fused 9 or 10 membered heterobicyclic ring system containing one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, wherein at least one of the rings in said ring system is aromatic; Ar2 represents an aromatic ring selected from phenyl, pyridyl, pyrimidinyl and pyridazinyl which is optionally fused and substituted; R1 represents halogen, hydroxy, oxo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkoxy, C3-7cycloalkyl, C3-7cycloalkoxy, C3-5cycloalkylC1-4alkyl, cyano, nitro, SR6, SOR6, SO2R6, COR6, NR3COR6, CONR3R4, NR3SO2R6, SO2NR3R4, -(CH2)mcarboxy, esterified -(CH2)mcarboxy or -(CH2)mNR3R4; R2 represents hydrogen, halogen, hydroxy, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy, haloC1-6alkoxy, unsubstituted phenyl or phenyl substituted with one or two groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or haloC1-6alkoxy; R3 and R4 are each independently hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl or fluoroC1-6alkyl; or R3 and R4 and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C1-4alkoxy, which ring may optionally contain as one of the said ring atoms an oxygen or a sulfur atom, S(O), S(O)2, or NR5; R5 represents hydrogen, C1-4alkyl, hydroxyC1-4alkyl or C1-4alkoxyC1-4alkyl; R6 represents hydrogen, C1-6alkyl, fluoroC1-6alkyl, C3-7cycloalkyl, unsubstituted phenyl, or phenyl substituted with one or two groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or haloC1-6alkoxy; m is either zero or an integer from 1 to 4; n is either zero or an integer from 1 to 3; or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof; a pharmaceutical composition comprising it; its use in methods of treatment; use of it for the manufacture of a medicament for treating VR-1 related conditions such as those in which pain and/or inflammation predominate; and methods of treatment using it.